Skip to Main Content

Paper Details

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Invest New Drugs
7
2018
Author NameAffiliation
Susan GeyerUniversity of South Florida
  • 1 - 1

Datasets

Release 1.2